(FOE lik AS id, sye an oh koe BAL a min, & peer i DOKS een)
Nutritional supplement in end-stage renal failure, dialysis, hyperhomocysteinemia, homocystinuria, malabsorption syndromes, dietary deficiencies
Hypersensitivity to folic acid, cyanocobalamin, pyridoxine, or any component of the formulation
Dietary supplement: Oral: One tablet daily
Refer to adult dosing.
Store at controlled room temperature of 15 ‚ °C to 30 ‚ °C (59 ‚ °F to 96 ‚ °F).
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Capsule, Oral:
Generic: Folic acid 1 mg, cyanocobalamin 400 mcg, and pyridoxine hydrochloride 50 mg
Tablet, Oral:
Airavite: Folic acid 2.5 mg, cyanocobalamin 1000 mcg, and pyridoxine hydrochloride 25 mg
Av-VITE FB: Folic acid 2.5 mg, cyanocobalamin 1000 mcg, and pyridoxine hydrochloride 25 mg
CenFol: Folic acid 2.3 mg, cyanocobalamin 2000 mcg, and pyridoxine hydrochloride 24.5 mg
FaBB: Folic acid 2.2 mg, cyanocobalamin 1000 mcg, and pyridoxine hydrochloride 25 mg
Folastin: Folic acid 2.5 mg, cyanocobalamin 2000 mcg, and pyridoxine hydrochloride 25 mg [DSC]
Folbee: Folic acid 2.5 mg, cyanocobalamin 1000 mcg, and pyridoxine hydrochloride 25 mg [dye free, lactose free, and sugar free]
Folbic: Folic acid 2.5 mg, cyanocobalamin 2000 mcg, and pyridoxine hydrochloride 25 mg
Folcaps: Folic acid 2.2 mg, cyanocobalamin 500 mcg, and pyridoxine hydrochloride 25 mg [sugar free] [DSC]
Folgard RX: Folic acid 2.2 mg, cyanocobalamin 1000 mcg, and pyridoxine hydrochloride 25 mg
Folplex 2.2: Folic acid 2.2 mg, cyanocobalamin 500 mcg, and pyridoxine hydrochloride 25 mg
Foltabs 800: Folic acid 0.8 mg, cyanocobalamin 115 mcg, and pyridoxine hydrochloride 10 mg [gluten free]
Homocysteine Formula: Folic acid 0.8 mg, cyanocobalamin 100 mcg, and pyridoxine hydrochloride 50 mg
Niva-Fol: Folic acid 2.5 mg, cyanocobalamin 2000 mcg, and pyridoxine hydrochloride 25 mg
NuFol: Folic acid 2.5 mg, cyanocobalamin 1000 mcg, and pyridoxine hydrochloride 25 mg
Virt-Gard: Folic acid 2.2 mg, cyanocobalamin 1000 mcg, and pyridoxine hydrochloride 25 mg
Virt-Vite: Folic acid 2.5 mg, cyanocobalamin 1000 mcg, and pyridoxine hydrochloride 25 mg
Virt-Vite Forte: Folic acid 2.5 mg, cyanocobalamin 2000 mcg, and pyridoxine hydrochloride 25 mg
Vita-Respa: Folic acid 2.2 mg, cyanocobalamin 1300 mcg, and pyridoxine hydrochloride 25 mg [dye free and sugar free]
Generic: Folic acid 0.5 mg, cyanocobalamin 200 mcg, pyridoxine hydrochloride 5 mg; Folic acid 0.8 mg, cyanocobalamin 100 mcg, and pyridoxine hydrochloride 50 mg; Folic acid 2.2 mg, cyanocobalamin 500 mcg, and pyridoxine hydrochloride 25 mg; Folic acid 2.5 mg, cyanocobalamin 200 mcg, and pyridoxine hydrochloride 25 mg
Altretamine: Pyridoxine may diminish the therapeutic effect of Altretamine. Specifically when altretamine is used in combination with Cisplatin the response duration may be diminished. Consider therapy modification
Barbiturates: Pyridoxine may increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day) Monitor therapy
Chloramphenicol: May diminish the therapeutic effect of Vitamin B12. Monitor therapy
Colchicine: May decrease the serum concentration of Cyanocobalamin. Monitor therapy
Fosphenytoin: Folic Acid may decrease the serum concentration of Fosphenytoin. Monitor therapy
Fosphenytoin: Pyridoxine may increase the metabolism of Fosphenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily) Monitor therapy
Green Tea: May decrease the serum concentration of Folic Acid. Monitor therapy
Levodopa: Pyridoxine may diminish the therapeutic effect of Levodopa. Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will essentially eliminate the risk of this interaction. Consider therapy modification
PHENobarbital: Folic Acid may decrease the serum concentration of PHENobarbital. Monitor therapy
Phenytoin: Folic Acid may decrease the serum concentration of Phenytoin. Monitor therapy
Phenytoin: Pyridoxine may increase the metabolism of Phenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily) Monitor therapy
Primidone: Folic Acid may decrease the serum concentration of Primidone. Additionally, folic acid may decrease concentrations of active metabolites of primidone (e.g., phenobarbital). Monitor therapy
Raltitrexed: Folic Acid may diminish the therapeutic effect of Raltitrexed. Avoid combination
SulfaSALAzine: May decrease the serum concentration of Folic Acid. Monitor therapy
See individual agents.
See individual agents.
See individual agents.
- Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
- Have patient report immediately to prescriber severe nausea, severe vomiting, severe diarrhea, burning or numbness feeling, change in balance, or abnormal gait (HCAHPS).
- Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.